Sorafenib + Sorafenib
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
Jul 19, 2011 → Jun 23, 2015
NCT ID
NCT01271504About Sorafenib + Sorafenib
Sorafenib + Sorafenib is a phase 1/2 stage product being developed by Eisai for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01271504. Target conditions include Hepatocellular Carcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01271504 | Phase 1/2 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma